| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 12 | 2017 | 416 | 1.250 |
Why?
|
| Stroke | 19 | 2017 | 1154 | 1.250 |
Why?
|
| Angioplasty | 8 | 2014 | 68 | 0.740 |
Why?
|
| Carotid Stenosis | 5 | 2012 | 116 | 0.730 |
Why?
|
| Stents | 10 | 2012 | 433 | 0.700 |
Why?
|
| Ischemic Attack, Transient | 4 | 2017 | 195 | 0.680 |
Why?
|
| Ovarian Neoplasms | 3 | 2016 | 826 | 0.580 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 40 | 0.500 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2016 | 6 | 0.490 |
Why?
|
| Embolization, Therapeutic | 5 | 2016 | 316 | 0.490 |
Why?
|
| Chemoprevention | 1 | 2016 | 93 | 0.470 |
Why?
|
| Thrombolytic Therapy | 8 | 2012 | 259 | 0.470 |
Why?
|
| Progesterone | 1 | 2016 | 126 | 0.460 |
Why?
|
| Vertebral Artery Dissection | 3 | 2012 | 24 | 0.460 |
Why?
|
| Calcitriol | 1 | 2016 | 173 | 0.450 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2012 | 180 | 0.410 |
Why?
|
| Angioplasty, Balloon | 3 | 2012 | 91 | 0.390 |
Why?
|
| Endovascular Procedures | 7 | 2016 | 398 | 0.370 |
Why?
|
| Carotid Artery, Internal | 3 | 2009 | 74 | 0.370 |
Why?
|
| Intracranial Aneurysm | 4 | 2016 | 239 | 0.320 |
Why?
|
| Fibrinolytic Agents | 8 | 2012 | 242 | 0.320 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 78 | 0.310 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 82 | 0.300 |
Why?
|
| Hypovolemia | 1 | 2008 | 3 | 0.290 |
Why?
|
| Drinking | 1 | 2008 | 34 | 0.290 |
Why?
|
| Dehydration | 1 | 2008 | 22 | 0.290 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 176 | 0.280 |
Why?
|
| Evolution, Molecular | 2 | 2016 | 902 | 0.270 |
Why?
|
| Minnesota | 7 | 2017 | 64 | 0.260 |
Why?
|
| Vasospasm, Intracranial | 3 | 2014 | 38 | 0.260 |
Why?
|
| Humans | 55 | 2017 | 97883 | 0.250 |
Why?
|
| Models, Molecular | 2 | 2016 | 1391 | 0.250 |
Why?
|
| Moyamoya Disease | 1 | 2007 | 25 | 0.250 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2014 | 158 | 0.240 |
Why?
|
| Risk Factors | 16 | 2015 | 6224 | 0.240 |
Why?
|
| Endarterectomy, Carotid | 3 | 2012 | 74 | 0.240 |
Why?
|
| Female | 39 | 2017 | 51464 | 0.240 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 12 | 0.230 |
Why?
|
| Aged | 29 | 2015 | 21702 | 0.230 |
Why?
|
| Time-to-Treatment | 3 | 2017 | 156 | 0.220 |
Why?
|
| Middle Aged | 32 | 2017 | 29353 | 0.220 |
Why?
|
| Seizures | 1 | 2008 | 318 | 0.220 |
Why?
|
| Patient Admission | 2 | 2017 | 122 | 0.210 |
Why?
|
| Aged, 80 and over | 16 | 2015 | 7386 | 0.210 |
Why?
|
| Emergency Medical Services | 3 | 2013 | 286 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 467 | 0.200 |
Why?
|
| Time Factors | 12 | 2017 | 5555 | 0.200 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 52 | 0.200 |
Why?
|
| Male | 35 | 2017 | 46992 | 0.190 |
Why?
|
| Retrospective Studies | 17 | 2017 | 10947 | 0.190 |
Why?
|
| Emergency Service, Hospital | 4 | 2014 | 619 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 2555 | 0.180 |
Why?
|
| Treatment Outcome | 18 | 2016 | 9682 | 0.170 |
Why?
|
| Chi-Square Distribution | 6 | 2014 | 359 | 0.170 |
Why?
|
| Vasodilator Agents | 2 | 2014 | 133 | 0.170 |
Why?
|
| Breast | 1 | 2013 | 315 | 0.170 |
Why?
|
| Patient Selection | 5 | 2012 | 720 | 0.170 |
Why?
|
| Genes, BRCA2 | 3 | 2015 | 162 | 0.160 |
Why?
|
| Carotid Artery Diseases | 2 | 2011 | 101 | 0.160 |
Why?
|
| Genes, BRCA1 | 3 | 2015 | 191 | 0.160 |
Why?
|
| Adult | 20 | 2017 | 29453 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 2 | 2012 | 138 | 0.160 |
Why?
|
| Cerebral Angiography | 3 | 2012 | 263 | 0.160 |
Why?
|
| Body Mass Index | 1 | 2013 | 851 | 0.150 |
Why?
|
| Signal Transduction | 1 | 2010 | 3623 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2014 | 2666 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2015 | 2580 | 0.140 |
Why?
|
| Aneurysm, Ruptured | 2 | 2016 | 79 | 0.140 |
Why?
|
| Morphine Derivatives | 1 | 2017 | 8 | 0.130 |
Why?
|
| Botulism | 1 | 2017 | 6 | 0.130 |
Why?
|
| Heroin Dependence | 1 | 2017 | 16 | 0.130 |
Why?
|
| Wound Infection | 1 | 2017 | 17 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 3272 | 0.130 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 141 | 0.130 |
Why?
|
| Abscess | 1 | 2017 | 94 | 0.130 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2017 | 7 | 0.130 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 16 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 39 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 91 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1778 | 0.120 |
Why?
|
| United States | 11 | 2014 | 8184 | 0.120 |
Why?
|
| Norepinephrine | 1 | 2017 | 166 | 0.120 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Calcium Signaling | 1 | 2017 | 142 | 0.120 |
Why?
|
| Registries | 5 | 2015 | 1120 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2016 | 317 | 0.120 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2016 | 57 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 257 | 0.110 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 57 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 207 | 0.110 |
Why?
|
| Ovary | 1 | 2016 | 260 | 0.110 |
Why?
|
| Logistic Models | 5 | 2014 | 1273 | 0.110 |
Why?
|
| Radiography | 3 | 2012 | 762 | 0.110 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 13 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 402 | 0.110 |
Why?
|
| Brain Infarction | 2 | 2013 | 23 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2373 | 0.110 |
Why?
|
| Age Factors | 5 | 2015 | 1960 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2014 | 724 | 0.100 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 39 | 0.100 |
Why?
|
| Cell Survival | 1 | 2016 | 1014 | 0.100 |
Why?
|
| Emergency Medical Technicians | 1 | 2013 | 14 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2013 | 15 | 0.100 |
Why?
|
| Binding Sites | 3 | 2016 | 1158 | 0.100 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2013 | 8 | 0.100 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2013 | 13 | 0.100 |
Why?
|
| Embolism, Air | 1 | 2013 | 21 | 0.100 |
Why?
|
| Advance Directives | 1 | 2013 | 64 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1567 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 72 | 0.090 |
Why?
|
| Lynch Syndrome II | 1 | 2012 | 1 | 0.090 |
Why?
|
| Talc | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2012 | 9 | 0.090 |
Why?
|
| Hemostatic Techniques | 1 | 2012 | 17 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2012 | 518 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 22 | 0.090 |
Why?
|
| Gonadotropins | 1 | 2012 | 32 | 0.090 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 18 | 0.090 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 12 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 242 | 0.090 |
Why?
|
| General Practice | 1 | 2011 | 9 | 0.090 |
Why?
|
| Parity | 1 | 2012 | 96 | 0.090 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2011 | 3 | 0.090 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2011 | 34 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 210 | 0.090 |
Why?
|
| Femoral Artery | 1 | 2012 | 96 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2012 | 62 | 0.090 |
Why?
|
| Endometriosis | 1 | 2012 | 67 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 396 | 0.080 |
Why?
|
| Androgens | 1 | 2012 | 164 | 0.080 |
Why?
|
| Stroke Rehabilitation | 1 | 2012 | 54 | 0.080 |
Why?
|
| Geography | 1 | 2012 | 249 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 169 | 0.080 |
Why?
|
| Aneurysm, False | 1 | 2011 | 52 | 0.080 |
Why?
|
| Epithelium | 1 | 2012 | 316 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2012 | 139 | 0.080 |
Why?
|
| Estrogens | 1 | 2012 | 202 | 0.080 |
Why?
|
| Life Style | 1 | 2012 | 193 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2010 | 25 | 0.080 |
Why?
|
| Recurrence | 3 | 2014 | 1254 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 104 | 0.080 |
Why?
|
| Self Care | 1 | 2012 | 188 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2012 | 197 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2012 | 113 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2012 | 174 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 249 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 74 | 0.080 |
Why?
|
| Thrombectomy | 1 | 2012 | 260 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1125 | 0.080 |
Why?
|
| Fluorescence | 1 | 2010 | 100 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2012 | 297 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2892 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2014 | 421 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2009 | 19 | 0.080 |
Why?
|
| Mutagenesis | 1 | 2010 | 195 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 168 | 0.070 |
Why?
|
| Nicardipine | 1 | 2009 | 6 | 0.070 |
Why?
|
| Patient Transfer | 1 | 2010 | 111 | 0.070 |
Why?
|
| Protein Conformation | 2 | 2010 | 925 | 0.070 |
Why?
|
| Magnesium Sulfate | 1 | 2009 | 17 | 0.070 |
Why?
|
| Thirst | 1 | 2008 | 19 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2010 | 225 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 470 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 166 | 0.070 |
Why?
|
| Diet | 1 | 2012 | 468 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3604 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2012 | 380 | 0.070 |
Why?
|
| Diuretics | 1 | 2008 | 77 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 255 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 1776 | 0.070 |
Why?
|
| Exercise | 1 | 2012 | 380 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1995 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 220 | 0.070 |
Why?
|
| Ophthalmoplegia | 1 | 2008 | 12 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 131 | 0.070 |
Why?
|
| Length of Stay | 2 | 2011 | 869 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 685 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 674 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 29 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 2008 | 55 | 0.060 |
Why?
|
| Survival Rate | 4 | 2012 | 2040 | 0.060 |
Why?
|
| Emergencies | 1 | 2008 | 122 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 993 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2014 | 799 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 685 | 0.060 |
Why?
|
| Microsurgery | 1 | 2007 | 120 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2482 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1121 | 0.060 |
Why?
|
| Adolescent | 3 | 2016 | 10078 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1108 | 0.050 |
Why?
|
| Obesity | 1 | 2012 | 1061 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 304 | 0.050 |
Why?
|
| Pregnancy | 1 | 2012 | 3246 | 0.050 |
Why?
|
| Survivors | 1 | 2015 | 211 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 377 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2017 | 718 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 4396 | 0.050 |
Why?
|
| Prevalence | 3 | 2012 | 1384 | 0.050 |
Why?
|
| Postmenopause | 1 | 2013 | 109 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 118 | 0.050 |
Why?
|
| Transportation of Patients | 2 | 2013 | 36 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 169 | 0.050 |
Why?
|
| Prognosis | 2 | 2015 | 4112 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 402 | 0.050 |
Why?
|
| Neoplasms | 2 | 2015 | 3340 | 0.040 |
Why?
|
| Body Weight | 1 | 2013 | 455 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 12698 | 0.040 |
Why?
|
| Cerebral Arteries | 2 | 2014 | 75 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2012 | 107 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 446 | 0.040 |
Why?
|
| Equipment Design | 2 | 2013 | 425 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1193 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 512 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 667 | 0.040 |
Why?
|
| Acute Disease | 2 | 2013 | 857 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 557 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1009 | 0.040 |
Why?
|
| Mammography | 1 | 2013 | 504 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1284 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 1137 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 550 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 28899 | 0.030 |
Why?
|
| Comorbidity | 2 | 2012 | 1032 | 0.030 |
Why?
|
| Estrenes | 1 | 2017 | 7 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 15 | 0.030 |
Why?
|
| Boron Compounds | 1 | 2017 | 17 | 0.030 |
Why?
|
| Thapsigargin | 1 | 2017 | 56 | 0.030 |
Why?
|
| Isoproterenol | 1 | 2017 | 58 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2017 | 30 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2017 | 69 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 118 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 4023 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 113 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2680 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 86 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 679 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 150 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 273 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 247 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 334 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 327 | 0.030 |
Why?
|
| Serotonin | 1 | 2016 | 211 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 24 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 487 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1476 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 2008 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 33 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 280 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 94 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 123 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 15 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 7 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 35 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cerebral Revascularization | 1 | 2014 | 35 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 642 | 0.030 |
Why?
|
| Africa | 1 | 2014 | 112 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 75 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2014 | 36 | 0.030 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2013 | 6 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 218 | 0.030 |
Why?
|
| Community Participation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2015 | 227 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 132 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2014 | 54 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 422 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2014 | 97 | 0.020 |
Why?
|
| Silicones | 1 | 2013 | 21 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2014 | 185 | 0.020 |
Why?
|
| Universities | 1 | 2014 | 166 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 70 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2012 | 4798 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 156 | 0.020 |
Why?
|
| Brain Edema | 1 | 2013 | 55 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 582 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2012 | 37 | 0.020 |
Why?
|
| Punctures | 1 | 2012 | 29 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 129 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 299 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 29 | 0.020 |
Why?
|
| Triage | 1 | 2013 | 151 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 219 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 579 | 0.020 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2011 | 9 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2011 | 96 | 0.020 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 52 | 0.020 |
Why?
|
| Certification | 1 | 2012 | 67 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 309 | 0.020 |
Why?
|
| Hospitals, Rural | 1 | 2010 | 9 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 33 | 0.020 |
Why?
|
| Critical Care | 1 | 2014 | 462 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2013 | 391 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 411 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 234 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 902 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2011 | 268 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 478 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 375 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 7504 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2009 | 42 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 532 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 283 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 194 | 0.020 |
Why?
|
| Carotid Artery, External | 1 | 2008 | 9 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 762 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1781 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 1094 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 407 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1536 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 983 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 2000 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 863 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1527 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1609 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 106 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1750 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2007 | 119 | 0.020 |
Why?
|
| Hospitalization | 1 | 2011 | 982 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 246 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1764 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2009 | 909 | 0.010 |
Why?
|
| Synaptosomes | 1 | 2003 | 14 | 0.010 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2003 | 9 | 0.010 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2003 | 50 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2003 | 43 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 519 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 538 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 4070 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3606 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 2429 | 0.010 |
Why?
|